AChE bivalent inhibitors (Part II)

From Proteopedia

Revision as of 12:16, 20 April 2009

This page is a continuation of the page AChE bivalent inhibitors

• 1w4l TcAChE complex with bis-acting galanthamine derivative
• 1u65 TcAChE complex with anticancer prodrug CPT-11
• 1e3q TcAChE complex with BW284C51
• 1acl TcAChE complex with decamethonium
• 1eve TcAChE complex with Aricept
• 1jjb TcAChE complex with PEG-SH-350

Described in the page 'AChE inhibitors and substrates' (GAL; colored red) is an AChE inhibitor and it is currently used in therapy of the AD. Conjugate of GAL through (8 carbons, yellow) with a (blueviolet) called compound 3 has a larger affinity for AChE than that of GAL alone. This is similar to previously described cases of bivalent ligands.

A comparison between the in complex with TcAChE (1w4l) and the structure (1dx6) shows an identical binding mode of the GAL-moiety (transparent red) of compound 3 to that of GAL alone (blue) at the CAS. The PEG molecule (gray) is located at the active site of galanthamine/TcAChE structure. The alkyl linker spans the active-site gorge and phthalimido moiety of the compound 3 is situated near the Trp279 at the PAS. The compound 3 has larger affinity to TcAChE than GAL. It could be explained by increased number of interactions between compound 3 (which interacts not only with residues within CAS but also within PAS) and TcAChE in comparison to GAL.

The (yellow) interacted with 13 residues of the the from Trp84 at the bottom to Phe284 at the top (1u65). Nine of these residues were (Tyr70, Trp84, Tyr121, Trp279, Phe284, Phe330, Phe331, Tyr334, and His440; colored darkmagenta). The contacts made by the drug in the bottom of the gorge involved with Trp84, Tyr121, Phe331, and His440 and, especially, a stacking interaction with Phe330. The carbamate moiety of CPT-11 was located near the residues . So, the carbon C9 (shown in magenta) of the carbamate linkage in CPT-11, was 9.3 Å from Oγ, the nucleophilic atom within the three catalytic residues Ser200, His440, and Glu327. The steric clashes between CPT-11 and TcAChE residues prevented positioning CPT-11 near the Ser200 Oγ (where hydrolysis could occur), therefore, TcAChE can not hydrolyze CPT-11.

Similarly to the other AChE bivalent inhibitors, BW284C51 (BW) also binds the TcAChE (1e3q) at the both subsites: CAS and PAS of its . At the CAS, BW makes a cation-aromatic interaction via quaternary group with (colored orange), BW phenyl ring forms an aromatic-aromatic interaction with His440, there is also an electrostatic interaction between the BW proximal quaternary group and Glu199. Near the PAS, BW via its distal quaternary group interacts with (colored cyan) and forms an aromatic interaction with Tyr334. BW forms hydrogen bond with Tyr121 OH, and makes alkyl interactions with Phe331. The superposition of BW with two other AChE bivalent inhibitors (decamethonium, colored gray, 1acl) and (Aricept, colored blueviolet, 1eve) at the TcAChE active site reveals similar mode of binding. All these 3 inhibitors form cation-π and π-π interactions with active-site gorge aromatic residues (colored yellow). The superposition of reveals their similar position at the active site, but has a different trajectory from them. This causes the , which interacts stronger with BW than with DECA and E2020. However, the conformations of the other important residues at the active site are similar in all these inhibitor-TcAChE complexes. It has been shown experimentally that BW and E2020 bind to TcAChE approximately 100-fold stronger than DECA. These findings could be explained by several reasons: i) E2020 and BW are less flexible than DECA; ii) the aromatic groups of E2020 and BW form favourable π-π interactions with TcAChE aromatic residues, in contrast to DECA; and iii) and have aromatic groups and, therefore, occupy more volume and better fit the active-site gorge, than . Mutations at the mouse or chicken AChE residues, corresponding to the TcAChE (colored red), cause significant increase of inhibition constant values for all these 3 inhibitors, supporting the notion that these residues are critical for inhibitor-AChE binding.

is an untypical acetylcholinesterase inhibitor. It consists of heptameric polyethylene glycol with a thiol group at the terminus. This thiol group binds close to the , while its second terminus binds to the . PEG-SH-350 interacts with TcAChE also via system of the (represented by oxygens colored red). Two out of seven PEG-SH-350 ethylene glycol units are in a trans (colored blue), while the others are in ±gauche .

Among the most interesting drugs that have been designed to inhibit acetylcholinesterase are those that have two binding sites that bind both the peripheral and catatylic sites simultaneously. Such drugs bind highly specificly and strongly. A good example is .

It appears that the principal interaction between the aceylcholine and the enzyme is relatively newly discovered cation-pi interactions between the cationic moiety of the substrate and the many aromatic residues lining the catalytic gorge. Unlike most interatomic interactions in chemistry, cation-pi interactions are unusual in that their energy hardly changes as the cationic and aromatic ring centers vary between 4 and 7 Angstroms apart, and for a wide variety of relative orientations of the aromatic rings. This gives the substrate an energetically smooth ride down the gorge with few bumps or barriers to impede passage down the gorge.

Most acetylcholinesterases have a net negative charge and a large patch of negative potential around the entrance to the active site gorge, which may be useful to attract the positively charged acetycholine substrate to the site. As one travels down the gorge, this potential becomes increasingly more and more negative, reaching a peak at the active site at the base. Because of this potential, the peripherial site is thought to act like a substrate trap, that forces practically molecule of substrate that reaches the peripheral site to travel down the gorge to the active site, that probably contributes greatly to the extremely rapid rate of degrading the substrate. This whole enzyme therefore acts like a brilliantly designed natural vacuum cleaner that clears the neurotransmitter out of the synapse extremely quickly. Yet to be solved, however, is how the products clear the active site rapidly, whether back through the gorge, or out a back door on the other side of the protein that quickly opens each catalytic cycle (Trp 84 is actually near the surface of the 'underside' of the protein.)

References

• Felder CE, Harel M, Silman I, Sussman JL. Structure of a complex of the potent and specific inhibitor BW284C51 with Torpedo californica acetylcholinesterase. Acta Crystallogr D Biol Crystallogr. 2002 Oct;58(Pt 10 Pt 2):1765-71. Epub, 2002 Sep 28. PMID:12351819
• Kryger G, Silman I, Sussman JL. Structure of acetylcholinesterase complexed with E2020 (Aricept): implications for the design of new anti-Alzheimer drugs. Structure. 1999 Mar 15;7(3):297-307. PMID:10368299
• Harel M, Hyatt JL, Brumshtein B, Morton CL, Yoon KJ, Wadkins RM, Silman I, Sussman JL, Potter PM. The crystal structure of the complex of the anticancer prodrug 7-ethyl-10-[4-(1-piperidino)-1-piperidino]-carbonyloxycamptothecin (CPT-11) with Torpedo californica acetylcholinesterase provides a molecular explanation for its cholinergic action. Mol Pharmacol. 2005 Jun;67(6):1874-81. Epub 2005 Mar 16. PMID:15772291 doi:http://dx.doi.org/10.1124/mol.104.009944

• Sussman JL, Harel M, Frolow F, Oefner C, Goldman A, Toker L, Silman I. Atomic structure of acetylcholinesterase from Torpedo californica: a prototypic acetylcholine-binding protein. Science. 1991 Aug 23;253(5022):872-9. PMID:1678899
• Greenblatt HM, Guillou C, Guenard D, Argaman A, Botti S, Badet B, Thal C, Silman I, Sussman JL. The complex of a bivalent derivative of galanthamine with torpedo acetylcholinesterase displays drastic deformation of the active-site gorge: implications for structure-based drug design. J Am Chem Soc. 2004 Dec 1;126(47):15405-11. PMID:15563167 doi:http://dx.doi.org/10.1021/ja0466154
• Koellner G, Steiner T, Millard CB, Silman I, Sussman JL. A neutral molecule in a cation-binding site: specific binding of a PEG-SH to acetylcholinesterase from Torpedo californica. J Mol Biol. 2002 Jul 19;320(4):721-5. PMID:12095250